Beta-lactam/beta-lactamase inhibitor combinations
12 July 2021
5. New antibacterial agents, PK/PD & Stewardship, 1,5-hour Educational Workshop
5f. Other
•
2549
•
13:15
>
14:45
•
Beta-lactam/beta-lactamase inhibitor combinations
•
5. Antimicrobials & stewardship
5f. Other
Among new licensed agents, beta-lactam/beta-lactamase inhibitor combinations feature prominently. New inhibitors are being developed and rolled out, and knowledge is accumulating about the complex PK/PD of the combinations. This symposium aims to update the attendees with the latest important knowledge on these combination agents including clinical experience with the new combinations with broad-spectrum cephalosporins and carbapenems, the properties of older compared to the new inhibitors such as relebactam, enmetazobactam and durlobactam; the issues around determining the PK/PD of the combinations and the resulting challenges in setting breakpoints.
13:15
•
2549-1
•
Old and new BLIs compared
>
R.
Robert A.
BONOMO (Cleveland)
13:35
•
2549-2
•
Pharmacodynamics of BL/BLIs
>
M.
Markus
ZEITLINGER (Vienna)
13:55
•
2549-3
•
Breakpoint selection for BL/BLIs
>
J.
Joseph
MELETIADIS (Athens)
14:15
•
2549-4
•
Q&A/Discussion
|